TrialProceedings of the National Academy of Sciences of the United States of America2023

Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.

Nadia Bannoud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.